

Second clinic in Sweden starts treatment with CoreTherm® Eagle

The second clinic in Sweden has now successfully treated the first patients with benign prostatic enlargement using the new CoreTherm® Eagle, further expanding the adoption of our new platform.

"We are excited to see our second clinic in Sweden now up and running with CoreTherm® Eagle. The successful treatments of the first patients mark yet another important milestone in our continued rollout. Next step is to implement CoreTherm® Eagle at one of our Centers of Excellence in Denmark. Following this, we plan to expand the launch beyond the Nordic region, bringing the benefits of CoreTherm® Eagle to a broader international market," says Malin Melander, acting CEO and COO at ProstaLund.

CoreTherm® Eagle builds on the proven and well-established technology that has been developed and refined over 25 years in earlier CoreTherm® platforms, used in over 30,000 treatments for benign prostatic hyperplasia in the Nordics. The new CoreTherm® Eagle has undergone significant technical and component upgrades. Among other things, the calculation of recommended treatment goals has been automated and integrated into the new platform. This provides increased support for the user and further enhances ease of use.

For further information, please contact:

Malin Melander, acting CEO and Chief Operating Officer Telefon: + 46 (0) 735 24 79 51 E-post: malin.melander@prostalund.com

About CoreTherm®

CoreTherm® is a minimally invasive transurethral microwave thermotherapy for benign prostatic enlargement (BPH). The treatment is performed in an outpatient setting under local anaesthesia and takes less than 15 minutes. No general anaesthesia or spinal block is needed. Follow-up data five years after CoreTherm® treatment shows clinical outcomes comparable to those seen after surgery/TURP (transurethral resection of the prostate), but with lower risk of serious complications. For more information visit, www.coretherm.com.

PRESS RELEASE 17 June 2025 10:00:00 CEST



About ProstaLund

ProstaLund AB (publ) is a Swedish medtech company headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement (BPH). The company has patented the CoreTherm® Concept, a customised thermal treatment for BPE. ProstaLund is listed on Nasdaq First North Growth Market and has approximately 3,500 shareholders. For more information, visit www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden

Certified Adviser:

Västra Hamnen Corporate Finance AB Phone: +46 40 200 250 E-mail: ca@vhcorp.se

Attachments

Second clinic in Sweden starts treatment with CoreTherm® Eagle